Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00267046
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
HD12 for Advanced Stages
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- University of Cologne
- Registration Number
- NCT00265031
HD11 for Intermediate Stages
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1395
- Registration Number
- NCT00264953
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00262925
- Locations
- 🇺🇸
Mercy Hospital and Medical Center, Chicago, Illinois, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
- Conditions
- Interventions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 17
- Registration Number
- NCT00250718
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00225173
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 46
- Registration Number
- NCT00217425
- Locations
- 🇺🇸
Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States
🇺🇸Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸California Cancer Care, Incorporated - Greenbrae, Greenbrae, California, United States
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 90
- Registration Number
- NCT00215943
- Locations
- 🇺🇸
Morton Plant Hospital, Clearwater, Florida, United States
🇺🇸Fawcett Memorial Hospital, Port Charlotte, Florida, United States
🇺🇸Watson Clinic, Lakeland, Florida, United States
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- European Mantle Cell Lymphoma Network
- Target Recruit Count
- 360
- Registration Number
- NCT00209222
- Locations
- 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00211185
- Locations
- 🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.